BSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,339.00
- Market cap
- ₹66,012 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.7×Sector 46.1×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Other board meeting date announcements
All →HMT Board Meeting Date
HMT Ltd will hold a board meeting on 6 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The notice is advance intimation only.
Svarnim Trade Udyog Board Meeting Date
Svarnim Trade Udyog will hold a board meeting on 3 November 2026 to consider unaudited quarterly and half-year results. No amounts are stated.
Intrasoft Technologies Board Meeting Date
Intrasoft Technologies will hold a board meeting on 06-Nov-2026 to consider unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026. Trading window remains closed until 48 hours after the meeting.
Ruparel Food Products Board Meeting Date
Ruparel Food Products will hold a board meeting on 02-Nov-2026 to consider unaudited standalone and consolidated half-yearly financial results for September 2026. Trading window is closed from 01-Oct-2026.
Accedere Board Meeting Date
Accedere Limited intimated a board meeting on 4 November 2026 to consider its unaudited Q2 standalone and consolidated results. Trading window closure is also noted, so this is a future meeting notice.
Systematic Industries Board Meeting Date
Systematic Industries Limited intimates a board meeting on November 3, 2026, to consider unaudited standalone results for the half year ended September 30, 2026. The trading window is closed from October 1, 2026 until 48 hours after the results are declared.